GMP Inspectors Will Scrutinize Adverse Event Reporting Compliance
This article was originally published in The Pink Sheet Daily
Regular under-reporting of serious adverse event reports has spurred FDA to have its good manufacturing practice inspectors review dietary supplement firms’ AERs and reporting practices, FDA’s Fabricant says. Key compliance issues can tip off the agency that a company may be falling short on reporting.
You may also be interested in...
FDA officials acknowledge ensuring the accuracy of all claims consumers make online about products is impossible, but the agency will hold firms accountable for information on or linked to their Web sites
In its final adverse event reports labeling guidance documents released Sept. 1, FDA does not budge on defining "domestic address" as a full mailing address, or on recommending labels include statements directing consumers how to submit AERs
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.